Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Lung Neoplasms
  • Proto-Oncogene Proteins
  • Receptor, Epidermal Growth Factor
  • ras Proteins

abstract

  • KRAS mutations predicted shorter survival for patients with advanced lung adenocarcinomas. The presence of EGFR and KRAS mutations define distinct subsets of patients with lung adenocarcinomas and should be determined in patients when they are diagnosed with advanced disease. Clinical trial reports should include EGFR and KRAS mutation status along with other prognostic factors.

publication date

  • January 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3966555

Digital Object Identifier (DOI)

  • 10.1002/cncr.27730

PubMed ID

  • 22810899

Additional Document Info

start page

  • 356

end page

  • 62

volume

  • 119

number

  • 2